FoldRx
Acquired by Pfizer
Developing small molecule therapeutics for protein misfolding and aggregation diseases.
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
2004
Developing small molecule therapeutics for protein misfolding and aggregation diseases.
FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.
